Arboretum Ventures

Arboretum Ventures LLC is a venture capital firm based in Ann Arbor, Michigan, founded in 2002. It specializes in making seed-stage, early-stage, mid-stage, and growth capital investments, primarily within the healthcare sector. The firm focuses on various areas, including healthcare services, medical devices, diagnostics, healthcare information technology, therapeutics, technology-based healthcare services, and life science tools. Arboretum Ventures typically invests between $5 million and $15 million in companies, with a notable emphasis on opportunities in the Midwest and Michigan. The firm is dedicated to supporting innovative healthcare companies that are poised for growth and development.

Amanda Elder

Vice President of Finance

Jan Garfinkle

Founder and Managing Partner

Sarah Jameson

Senior Associate

Dan Kidle

Managing Partner

Marcy Marshall

CFO

Paul McCreadie

Partner and COO

Suraj Mudichintala

Associate

Timothy B. Petersen

Founder and Managing Partner

Jon J. Snyder

Venture Partner

Nicole Walker

Managing Director

87 past transactions

Koya Medical

Series B in 2022
Koya Medical, Inc. develops technology device to treat cancer related chronic lymphedema and venous diseases. The company was founded in 2018 and is based in Oakland, California.

ViaLase

Series A in 2021
ViaLase develops an image-guided femtosecond laser surgical system for the treatment of glaucoma. ViaLase is headquartered in Corona Del Mar, California.

Convergent Dental

Series C in 2021
Convergent Dental is a privately owned dental equipment and technology company and developer of Sole, the world’s first computer-aided, CO2 laser system to ever be cleared by the FDA for both hard and soft tissue indications. Solea cuts significantly quieter, finer, and faster than any other laser-based system in dentistry. Solea’s speed and precision are a result of patented technologies and computer system controls that are unique to Convergent Dental, Inc. Convergent Dental unique system, with patented technologies and controls, nearly eliminates the need for the drill. The company was founded in 2011 and is based in Needham, Massachusetts, United States.

Akadeum Life Sciences

Series B in 2021
Akadeum Life Sciences is working on the problem of isolating mammalian and bacterial cells from complex mixtures. It creates the simplest bioseparation products and fundamentally change the way that isolating cells and other biological targets approached. The company currently uses microbubbles for applications in cell separation and other related areas. Akadeum Life Sciences was founded in 2014 and is headquartered in Ann Arbor, Michigan, United States.

Francis Medical

Series B in 2021
Francis Medical, Inc. is a medical technology company based in Maple Grove, Minnesota, founded in 2018. The company specializes in developing vapor ablation therapy devices aimed at treating various urological cancers, including prostate, kidney, and bladder cancers. Its innovative treatments utilize water vapor technology, which employs energy from a small amount of water to effectively ablate cancerous tissue. This method not only targets the cancer but also aims to safeguard surrounding healthy structures, thereby minimizing the risk of significant side effects often associated with traditional cancer treatments.

Allay Therapeutics

Series C in 2021
Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States.

RareCyte

Series G in 2021
RareCyte, Inc. is a life sciences company based in Seattle, Washington, that specializes in the development of liquid and tissue biopsy analysis platforms aimed at the detection of rare cells. Founded in 2009, RareCyte focuses on providing innovative technologies for the Life Sciences research, drug development, and diagnostic markets. The company offers a range of products, including sample preparation systems, staining kits, and automated fluorescence microscopy instruments. Its AccuCyte system is particularly notable for enabling the unbiased discovery and isolation of circulating tumor cells and circulating endothelial cells from whole blood. RareCyte's technologies are designed to address complex challenges in cancer and cardiovascular disease research, facilitating advancements in precision medicine and non-invasive prenatal testing.

Strata Oncology

Series C in 2021
Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.

Navv Systems

Seed Round in 2021
Navv Systems, is a software solutions and platform company that uses Indoor Positioning technology (IPS) to provide traffic control for hospitals, warehouses, manufacturing, and other large, complex organizations.

Flosonics

Venture Round in 2021
Flosonics is a medical device company that focuses on developing non-invasive sensors to improve the management of critically ill patients. Flosonics's flagship smart-bandage product, the FloPatch, addresses unmet clinical needs of critically ill patients and the physicians, nurses, and paramedics who care for them in the ambulance, emergency department, operating room, and intensive care unit.

EQRx

Series B in 2021
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

Koya Medical

Venture Round in 2020
Koya Medical, Inc. develops technology device to treat cancer related chronic lymphedema and venous diseases. The company was founded in 2018 and is based in Oakland, California.

Jumpcode Genomics

Funding Round in 2020
JUMPCODE's CRISPR-mediated rRNA depletion kits remove nucleic acids from sequencing workflows to improve sensitivity and performance. CRISPRclean is a proprietary technology that utilizes the CRISPR/CAS system to cut through the noise by removing unwanted nucleic acid molecules from sequencing libraries while preserving the representational integrity of the non-targeted sequences. Keith Brown founded the company in Carlsbad, California in 2016.

Cardiac Dimensions

Series C in 2020
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

Health Scholars

Series B in 2020
Health Scholars is a developer of medical simulation training software intended to provide clinical education and training. The company's platform is easy to use and scalable across a health system and effectively manages, delivers and includes interactive training content including the only commercially available as well as clinical VR simulation, enabling users to get cost-effective and richer content experience.

EQRx

Series A in 2020
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

Fifth Eye

Series A in 2019
Fifth Eye Inc., a medical software company, develops a real time analytics system designed to analyze hemodynamic instability in patients. It offers early warning system that continuously forecasts patient trajectory, giving doctors and nurses a heads up about impending trouble hours in advance of other methods. The company's tool provides first score in five minutes with no baseline needed, minute-to-minute continuous patient assessment, advance warning and real-time treatment feedback, and historical trends without the need for electronic health record inputs. The company was formerly known as Trove Analytics, Inc. and changed its name to Fifth Eye Inc. in June 2018. Fifth Eye Inc. was incorporated in 2017 and is based in Ann Arbor, Michigan.

Lucina Health

Seed Round in 2019
Lucina Health, Inc. is a data-driven enterprise software company based in Louisville, Kentucky, specializing in maternity analytics. The company provides a platform called Firefly, which aggregates and analyzes patient and population data in real-time. This platform is designed for health plans, Medicaid providers, and public entities, enabling them to improve health outcomes and reduce costs. Firefly includes a mobile app that facilitates communication between healthcare providers and patients, empowering women to manage their pregnancies effectively. Additionally, Lucina Health focuses on identifying women at risk of preterm birth, often within the first trimester, and offers personalized resources to support their health. By serving mothers, care managers, and communities, Lucina Health aims to enhance birth outcomes and foster healthier populations over time. The company, originally known as Cervilenz Inc., was rebranded in September 2015 and operates as a subsidiary of Unified Women's Healthcare LLC.

Pear Therapeutics

Series C in 2019
Pear Therapeutics, Inc. focuses on developing and delivering clinically validated software-based therapeutics aimed at treating behavioral health disorders, including psychiatric and neurologic conditions. The company creates digital therapies for severe conditions such as addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and chronic insomnia. Its key products include mobile digital therapies that incentivize patients for completing treatment modules, reSET for substance use disorder, reSET-O for opioid use disorder, and Somryst for insomnia. Additionally, Pear Therapeutics offers PearConnect, a comprehensive patient services center that provides support for patients throughout their treatment journey, connects healthcare providers to resources, and assists insurance companies with claims processing. Founded in 2013, Pear Therapeutics is headquartered in Boston, Massachusetts, with an additional office in San Francisco, California.

SonarMD

Series A in 2018
SonarMD, LLC develops subspecialty practice platform for medical purpose. The company is based in Elgin, Illinois.

Francis Medical

Series A in 2018
Francis Medical, Inc. is a medical technology company based in Maple Grove, Minnesota, founded in 2018. The company specializes in developing vapor ablation therapy devices aimed at treating various urological cancers, including prostate, kidney, and bladder cancers. Its innovative treatments utilize water vapor technology, which employs energy from a small amount of water to effectively ablate cancerous tissue. This method not only targets the cancer but also aims to safeguard surrounding healthy structures, thereby minimizing the risk of significant side effects often associated with traditional cancer treatments.

Strata Oncology

Series B in 2018
Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.

Cardiac Dimensions

Series B in 2018
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

BioIQ

Venture Round in 2018
BioIQ, Inc., a healthcare engagement and quality care company, develops health measurement software solutions to individuals. The company offers humanize analytics, analytics and omnichannel communications, and care navigation ecosystem for health plans, employers, and government. It serves national laboratories, diagnostics companies, digital health solutions, etc. The company was founded in 2005 and is based in Atlanta, Georgia.

Pear Therapeutics

Series B in 2018
Pear Therapeutics, Inc. focuses on developing and delivering clinically validated software-based therapeutics aimed at treating behavioral health disorders, including psychiatric and neurologic conditions. The company creates digital therapies for severe conditions such as addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and chronic insomnia. Its key products include mobile digital therapies that incentivize patients for completing treatment modules, reSET for substance use disorder, reSET-O for opioid use disorder, and Somryst for insomnia. Additionally, Pear Therapeutics offers PearConnect, a comprehensive patient services center that provides support for patients throughout their treatment journey, connects healthcare providers to resources, and assists insurance companies with claims processing. Founded in 2013, Pear Therapeutics is headquartered in Boston, Massachusetts, with an additional office in San Francisco, California.

Swift Biosciences

Series D in 2017
Swift Biosciences Inc. is a biotechnology company based in Ann Arbor, Michigan, specializing in the development and commercialization of next-generation sequencing (NGS) library preparation kits for genomics and clinical research. The company offers a comprehensive range of products, including RNA library kits, amplicon panels, hybridization capture kits, and specialized kits for cancer gene profiling and COVID-19 testing. Swift Biosciences aims to streamline NGS sample preparation processes through innovative reagents and protocols, enhancing the usability of data obtained from sequencing instruments. Its offerings cater to various applications such as whole-genome sequencing, metagenomics, and the analysis of circulating tumor cells. The company operates through a network of distributors across the Asia Pacific, Europe, the Middle East, and South America, and was incorporated in 2009.

Aira

Series B in 2017
Aira Tech Corp. is dedicated to enhancing accessibility for blind and low-vision individuals through its innovative online platform, which acts as a visual interpreter and navigator. The service connects users with trained agents, family members, or friends for remote assistance, utilizing smart glasses linked to the user’s smartphone. By simply downloading the app and activating the camera, users can stream live video to highly screened visual interpreters who provide real-time guidance and support. Founded in 2015 and headquartered in La Jolla, California, Aira aims to make the world more accessible, ensuring that individuals can navigate their environments with greater independence and confidence. The platform has been recognized for its significant impact, being described as a "Godsend" by The New York Times.

Ebb Therapeutics

Series B in 2017
Ebb Therapeutics, Inc. develops regional cerebral thermal therapy (RCTT) device for use in insomnia and sleep disorders. It offers Ebb Insomnia Therapy, a drug-free insomnia therapy. Ebb Therapeutics, Inc. was formerly known as Cereve, Inc. Ebb Therapeutics, Inc. was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.

ConcertoCare

Venture Round in 2016
ConcertoCare provides healthcare services primarily to dual-eligible patients enrolled in Medicare and Medicaid, as well as those with complex medical needs. The company focuses on addressing critical vulnerabilities faced by these patients and health plans by offering personalized primary care, chronic condition management, and support for transitions between various care settings. Additionally, ConcertoCare delivers medical, social, and logistical assistance to enhance patient outcomes. Founded in 2004 and based in Aliso Viejo, California, the company operates care centers in locations including Renton, Washington, and several cities in Michigan. The name Concerto reflects its holistic approach to healthcare, emphasizing collaboration among patients, providers, and health plans to ensure coordinated care that respects the dignity and health of each individual.

nVision Medical

Series B in 2016
NVISION MEDICAL Corporation operates in the healthcare sector. The company was incorporated in 2009 and is based in Saratoga, California. nVision is a privately-held medical device company dedicated to filling the void in women’s health innovation. Since its founding in 2011, the company has relentlessly focused on developing devices to enable clinicians to assess the health of previously inaccessible parts of the female reproductive tract.

SI-BONE

Venture Round in 2016
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was founded in 2008 and is headquartered in Santa Clara, California.

Strata Oncology

Series A in 2016
Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.

ArborMetrix

Series B in 2016
ArborMetrix, Inc. specializes in data analytics and technology solutions aimed at enhancing outcomes and advancing research within the healthcare industry. The company offers a platform that facilitates data collection and integration, performance measurement, and analytics, along with comprehensive database administration. Its solutions include EpisodeMetrix, which analyzes episode costs to help healthcare payers and providers optimize networks and manage care costs, and RegistryMetrix, designed for creating tailored clinical registries. Additionally, SurgicalMetrix provides insights into the performance of surgical groups by integrating various clinical and operational data. ArborMetrix’s offerings also encompass clinical quality improvement, patient and provider engagement, value-based reimbursement, and clinical research. The company serves a diverse range of clients, including specialty societies, medical device manufacturers, pharmaceutical companies, and health systems across the United States. Founded in 2011, ArborMetrix is headquartered in Ann Arbor, Michigan.

Pear Therapeutics

Series A in 2016
Pear Therapeutics, Inc. focuses on developing and delivering clinically validated software-based therapeutics aimed at treating behavioral health disorders, including psychiatric and neurologic conditions. The company creates digital therapies for severe conditions such as addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and chronic insomnia. Its key products include mobile digital therapies that incentivize patients for completing treatment modules, reSET for substance use disorder, reSET-O for opioid use disorder, and Somryst for insomnia. Additionally, Pear Therapeutics offers PearConnect, a comprehensive patient services center that provides support for patients throughout their treatment journey, connects healthcare providers to resources, and assists insurance companies with claims processing. Founded in 2013, Pear Therapeutics is headquartered in Boston, Massachusetts, with an additional office in San Francisco, California.

Intellicyt

Venture Round in 2015
IntelliCyt Corporation specializes in developing and marketing high-throughput cell and bead-based screening solutions for the life sciences sector. Established in 2006 and based in Albuquerque, New Mexico, the company offers innovative products, including the iQue Screener platform, which integrates instruments, software, and reagents for high-content multiplexed analysis of cell and bead samples. IntelliCyt's ForeCyt software facilitates data visualization and analysis, while its MultiCyt screening kits provide essential reagents for use with iQue Screeners. These solutions significantly enhance the speed and cost-effectiveness of detecting and measuring cells, catering to the needs of pharmaceutical and biotechnology companies, as well as medical research institutions. By combining flow cytometry with patented sample processing technology, IntelliCyt has created a platform that accelerates suspension cell assays, enabling researchers to achieve higher productivity in drug discovery, antibody development, and toxicology studies. The company also provides installation, training, and technical support services to its clients. IntelliCyt operates as a subsidiary of Sartorius AG.
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presence of benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan.

Cardiac Dimensions

Series A in 2015
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

My Health Direct

Venture Round in 2014
My Health Direct, Inc. develops a digital care coordination solution designed to enhance healthcare access and streamline appointment scheduling. Its primary product, MyHealthDirect, is a referral management and online appointment-scheduling platform that facilitates actionable analytics, decision support, and workflow management for various healthcare entities, including health systems, physician practices, and community health organizations. The platform organizes and books available healthcare appointments into a searchable inventory, allowing for efficient scheduling on behalf of individuals. Founded in 2006 and originally known as Global Health Direct, the company is headquartered in Nashville, Tennessee, and operates as a subsidiary of Experian Health, Inc.

Cardiac Dimensions

Series A in 2014
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

Rethink First

Series C in 2014
Rethink Autism, Inc. is a global health technology company that specializes in cloud-based treatment tools, training, and clinical support for individuals with developmental disabilities and their caregivers. It offers a range of products, including Rethink Behavioral Health, which provides comprehensive tools for clinical solutions and practice management for behavioral health providers. The company also features Rethink Benefits, designed for Fortune 500 corporations, which offers web-based training tools to implement clinical best practices for employees. Additionally, Rethink Ed supplies a software management platform that allows educational institutions to design, deliver, and monitor evidence-based practices, supporting schools across the United States and military base school systems worldwide. Rethink Autism's platform integrates a proven treatment methodology with a video-based curriculum, offering training, evaluation tools, and data management systems to ensure effective treatment implementation. Founded in 2007 and based in New York, the company was previously known as Treat Autism Now, Inc. before rebranding in 2008.

NeuMoDx Molecular

Series B in 2014
NeuMoDx Molecular, Inc. is a molecular diagnostics company focused on developing solutions for molecular diagnostic testing in hospital and clinical reference laboratories. Established in 2012 and based in Ann Arbor, Michigan, the company was formerly known as Molecular Systems Corporation before rebranding in April 2013. As of September 2020, NeuMoDx operates as a subsidiary of QIAGEN N.V. Its innovative products aim to enhance the efficiency and accuracy of molecular testing, contributing to better patient outcomes in various healthcare settings.

Advance Medical

Series B in 2013
Advance Medical is one of the largest, physician-based telemedicine providers, offering employers and insurers the ability to provide top-quality, concierge-level medical advice and support to patients around the globe via offices in the U.S., Europe, Asia, and South America. Founded in 1999, Advance Medical has emerged as the global leader in expert medical opinions because of its programs executed exclusively by board-certified physicians – doctors who speak by phone or video consultation with every patient, no matter what the issue or concern and for as much time as necessary, to provide best-in-class medical expertise.

Adavium

Private Equity Round in 2013
Adavium Medical is a medical equipment and diagnostics company aimed at bringing commercial sophistication to a highly fragmented market. The Company was formed with the intent to commercialize the most innovative portfolio of medical device and diagnostics products in Brazil. Adavium Medical portfolio today is made up of products that we commercialize on behalf of leading international companies. Adavium Medical assembled an experienced team of more than 300 employees that ensure that its fully-integrated commercial platform operates at world-class standards. Adavium Medical have the largest customer base across premium and “long tail” customers of any medical equipment and/or diagnostics company in Brazil, with more than 2,500 customers respectively in medical equipment and diagnostics. This is exponentially more than the average distributor or multinational in the region. The company was founded in 2011 and is headquartered in Sao Paulo, Brazil.
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presence of benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan.

ArborMetrix

Series B in 2013
ArborMetrix, Inc. specializes in data analytics and technology solutions aimed at enhancing outcomes and advancing research within the healthcare industry. The company offers a platform that facilitates data collection and integration, performance measurement, and analytics, along with comprehensive database administration. Its solutions include EpisodeMetrix, which analyzes episode costs to help healthcare payers and providers optimize networks and manage care costs, and RegistryMetrix, designed for creating tailored clinical registries. Additionally, SurgicalMetrix provides insights into the performance of surgical groups by integrating various clinical and operational data. ArborMetrix’s offerings also encompass clinical quality improvement, patient and provider engagement, value-based reimbursement, and clinical research. The company serves a diverse range of clients, including specialty societies, medical device manufacturers, pharmaceutical companies, and health systems across the United States. Founded in 2011, ArborMetrix is headquartered in Ann Arbor, Michigan.

Fidelis SeniorCare

Series A in 2013
Fidelis SeniorCare, Inc., a managed care company, develops and administers health plans for assisted living residents in Michigan, North Carolina, and Texas. The company offers Medicare advantage special needs plans to cover the health needs of seniors living in nursing homes and assisted living communities; and individuals who require specialized healthcare. Its plans cover on-site primary care team visits, part D prescription drugs, monitoring and managing prescribed medications, transportation to the hospital or physician’s office, and skilled nursing services during a covered Medicare stay; preventive care, screening, vision/dental/hearing, and podiatry services; and emergency room, ambulance, and urgent care services. The company was founded in 2004 and is based in Schaumburg, Illinois.

Intellicyt

Venture Round in 2013
IntelliCyt Corporation specializes in developing and marketing high-throughput cell and bead-based screening solutions for the life sciences sector. Established in 2006 and based in Albuquerque, New Mexico, the company offers innovative products, including the iQue Screener platform, which integrates instruments, software, and reagents for high-content multiplexed analysis of cell and bead samples. IntelliCyt's ForeCyt software facilitates data visualization and analysis, while its MultiCyt screening kits provide essential reagents for use with iQue Screeners. These solutions significantly enhance the speed and cost-effectiveness of detecting and measuring cells, catering to the needs of pharmaceutical and biotechnology companies, as well as medical research institutions. By combining flow cytometry with patented sample processing technology, IntelliCyt has created a platform that accelerates suspension cell assays, enabling researchers to achieve higher productivity in drug discovery, antibody development, and toxicology studies. The company also provides installation, training, and technical support services to its clients. IntelliCyt operates as a subsidiary of Sartorius AG.

Esperion

Venture Round in 2013
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). Founded in 2008 and headquartered in Ann Arbor, Michigan, the company specializes in non-statin medications aimed at treating conditions such as atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia. Its primary product candidates include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which are designed to improve cholesterol management. Esperion also explores novel treatment approaches, including HDL Therapy, based on its understanding of high-density lipoprotein function. The company collaborates with Daiichi Sankyo Europe GmbH to enhance its research and development efforts.

BAROnova

Series C in 2013
BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and based in Goleta, California. The company specializes in developing non-surgical and non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a simple endoscopic procedure. This device helps patients feel full more quickly, prolongs the sensation of fullness, and delays gastric emptying, thereby supporting weight loss efforts.
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Tangent Medical Technologies

Venture Round in 2012
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Sonitus Medical

Series D in 2012
Sonitus Medical Inc., is a privately held medical device company committed to providing innovative and clinically effective hearing solutions that Otologists, ENTs, and Audiologists can use to help their patients rejoin the conversation of life. As an emerging leader in bone conduction hearing devices, Sonitus Medical currently markets the SoundBite Hearing System, the world's first non-invasive and removable hearing solution that imperceptibly transmits sound via teeth. Relying on the principle of bone conduction, this nearly invisible ITM (in-the-mouth) hearing system is a simple and non-surgical solution that is currently FDA cleared as a prosthetic device for the treatment of single sided deafness and conductive hearing loss. Intended future applications for this platform technology include indications for hearing disorders such as mixed hearing loss and tinnitus, as well as consumer and covert communications. Founded in June 2006, Sonitus Medical is headquartered in San Mateo, California.

Uptake Medical

Series C in 2012
Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

Cervilenz

Series E in 2012
CerviLenz is a new, disposable device that measure vaginal cervical length during a speculum exam. Cervical length is a powerful predictor of preterm birth risk and influences patient management decisions. CerviLenz gives clinicians an immediate, reliable method for measuring the cervix at the point of care. CerviLenz is manufactured and distributed by Cervilenz Inc. headquartered in Chagrin Falls, Ohio.

Cervilenz

Series A in 2012
CerviLenz is a new, disposable device that measure vaginal cervical length during a speculum exam. Cervical length is a powerful predictor of preterm birth risk and influences patient management decisions. CerviLenz gives clinicians an immediate, reliable method for measuring the cervix at the point of care. CerviLenz is manufactured and distributed by Cervilenz Inc. headquartered in Chagrin Falls, Ohio.

Hicuity Health

Series D in 2011
Hicuity Health is a leading provider of high-acuity telehealth services, focused on enhancing intensive care unit (ICU) programs for hospitals across the United States. The company offers tele-ICU solutions that enable hospitals to improve patient care while optimizing clinical, operational, and financial performance. Hicuity Health employs advanced telemedicine technology to analyze real-time patient data and facilitate two-way video conferencing between care teams and patients. They provide round-the-clock clinical services to nearly 100 hospitals in 27 states, leveraging U.S. board-certified intensivists and dedicated tele-care delivery centers. Additionally, Hicuity Health supports hospitals with consulting services to enhance their ICU operations. Founded in 2004 and headquartered in St. Louis, Missouri, the company operates multiple centers nationwide, including locations in Texas, California, New York, Hawaii, South Carolina, and Washington, D.C.
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Cervilenz

Venture Round in 2011
CerviLenz is a new, disposable device that measure vaginal cervical length during a speculum exam. Cervical length is a powerful predictor of preterm birth risk and influences patient management decisions. CerviLenz gives clinicians an immediate, reliable method for measuring the cervix at the point of care. CerviLenz is manufactured and distributed by Cervilenz Inc. headquartered in Chagrin Falls, Ohio.

NxThera

Series B in 2011
NxThera develops medical technologies to treat a variety of endourology conditions, including BPH. The company's technology platform utilizes a simple, minimally invasive, vapor therapy designed to measurably improve urinary flow and patient quality of life. BPH afflicts more than 32 million men in the United States.

Wellfount

Series A in 2011
Wellfount Corp. offers pharmacy services to nursing facilities. The company offers utilization and compliance reviews, multi dose, compliance packaging used for cycle and routine meds, proprietary SOPs and clinical programs, daily deliveries, intravenous therapy (IV), total parenteral nutrition (TPN), customized invoicing, EHR application integration, and medical records. It also offers medications and consulting services. Wellfount Corp. was founded in 2006 and is based in Indianapolis, Indiana.

My Health Direct

Series B in 2011
My Health Direct, Inc. develops a digital care coordination solution designed to enhance healthcare access and streamline appointment scheduling. Its primary product, MyHealthDirect, is a referral management and online appointment-scheduling platform that facilitates actionable analytics, decision support, and workflow management for various healthcare entities, including health systems, physician practices, and community health organizations. The platform organizes and books available healthcare appointments into a searchable inventory, allowing for efficient scheduling on behalf of individuals. Founded in 2006 and originally known as Global Health Direct, the company is headquartered in Nashville, Tennessee, and operates as a subsidiary of Experian Health, Inc.

PathCentral

Series B in 2010
PathCentral, an Irvine, California-based provider of a fully integrated, web-based enterprise software platform designed specifically for community pathologists. Created by a team of pathologists and industry executives, PathCentral's solution integrates all aspects of a pathology practice's business, including ordering (accessioning), barcode-based laboratory workflow management and specimen tracking, transcription, test send-outs, professional consultations, diagnosis, reporting, billing and financial analysis.

Accuri Cytometers

Series E in 2010
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presence of benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan.

Uptake Medical

Series B in 2010
Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

CardioMEMS

Venture Round in 2010
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Their technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Their miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.

CardioMEMS

Series F in 2009
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Their technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Their miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.

Accuri Cytometers

Series D in 2009
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.

Cervilenz

Series A in 2009
CerviLenz is a new, disposable device that measure vaginal cervical length during a speculum exam. Cervical length is a powerful predictor of preterm birth risk and influences patient management decisions. CerviLenz gives clinicians an immediate, reliable method for measuring the cervix at the point of care. CerviLenz is manufactured and distributed by Cervilenz Inc. headquartered in Chagrin Falls, Ohio.

BAROnova

Series B in 2008
BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and based in Goleta, California. The company specializes in developing non-surgical and non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a simple endoscopic procedure. This device helps patients feel full more quickly, prolongs the sensation of fullness, and delays gastric emptying, thereby supporting weight loss efforts.

HandyLab

Series D in 2008
HandyLab is a medical technology company that develops and manufactures molecular diagnostic assays and automation platforms The company’s proprietary platform reduces the time, cost, and complexity of testing while improving the quality of results. Using patented real-time microfluidic PCR technology, its products are positioned to decentralize nucleic acid testing. HandyLab was founded in 2000 and is based in Ann Arbor, Michigan. It was acquired by Becton, Dickinson and Company in 2009.

Accuri Cytometers

Series C in 2008
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.

Hicuity Health

Series B in 2008
Hicuity Health is a leading provider of high-acuity telehealth services, focused on enhancing intensive care unit (ICU) programs for hospitals across the United States. The company offers tele-ICU solutions that enable hospitals to improve patient care while optimizing clinical, operational, and financial performance. Hicuity Health employs advanced telemedicine technology to analyze real-time patient data and facilitate two-way video conferencing between care teams and patients. They provide round-the-clock clinical services to nearly 100 hospitals in 27 states, leveraging U.S. board-certified intensivists and dedicated tele-care delivery centers. Additionally, Hicuity Health supports hospitals with consulting services to enhance their ICU operations. Founded in 2004 and headquartered in St. Louis, Missouri, the company operates multiple centers nationwide, including locations in Texas, California, New York, Hawaii, South Carolina, and Washington, D.C.

Esperion

Series A in 2008
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). Founded in 2008 and headquartered in Ann Arbor, Michigan, the company specializes in non-statin medications aimed at treating conditions such as atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia. Its primary product candidates include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which are designed to improve cholesterol management. Esperion also explores novel treatment approaches, including HDL Therapy, based on its understanding of high-density lipoprotein function. The company collaborates with Daiichi Sankyo Europe GmbH to enhance its research and development efforts.

Mirabilis Medical

Series A in 2007
Mirabilis Medical, Inc. is a medical device company based in Bothell, Washington, that specializes in the development and manufacture of ultrasound devices aimed at the non-invasive treatment of uterine fibroids, a common condition affecting women. Established in 2004, the company provides innovative solutions for gynecologists, utilizing high-resolution ultrasound imaging to accurately locate and treat fibroid tissue deep within the body without the need for incisions or punctures. This proprietary technology allows for effective ablation of pathological tissue while minimizing damage to surrounding areas, positioning Mirabilis Medical as a key player in the field of gynecological treatments.

KFx Medical

Series B in 2007
KFx Medical specializes in the development and manufacturing of innovative soft tissue fixation implants aimed at orthopedic sports medicine. The company provides a system designed for tissue fixation, offering products that can be directly placed into bones, both with and without sutures. These implants are utilized in various orthopedic surgical procedures, allowing surgeons to effectively reattach tissue in areas such as the shoulder, knee, foot, and ankle. By collaborating with leading orthopedic surgeons, KFx Medical focuses on advancing technology and delivering reliable surgical implants, ultimately aiming to enhance surgical outcomes for patients.

Accuri Cytometers

Series B in 2007
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.

Inogen

Series D in 2007
Inogen is innovation in oxygen therapy. Our mission is to improve freedom and independence for oxygen therapy patients through innovative products and services. As a manufacturer and Accredited Homecare Provider dedicated to oxygen therapy, Inogen is ideally suited to develop products tailored to oxygen therapy users and to provide superior service to those users in their homes.

Uptake Medical

Series A in 2006
Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

Hicuity Health

Series A in 2006
Hicuity Health is a leading provider of high-acuity telehealth services, focused on enhancing intensive care unit (ICU) programs for hospitals across the United States. The company offers tele-ICU solutions that enable hospitals to improve patient care while optimizing clinical, operational, and financial performance. Hicuity Health employs advanced telemedicine technology to analyze real-time patient data and facilitate two-way video conferencing between care teams and patients. They provide round-the-clock clinical services to nearly 100 hospitals in 27 states, leveraging U.S. board-certified intensivists and dedicated tele-care delivery centers. Additionally, Hicuity Health supports hospitals with consulting services to enhance their ICU operations. Founded in 2004 and headquartered in St. Louis, Missouri, the company operates multiple centers nationwide, including locations in Texas, California, New York, Hawaii, South Carolina, and Washington, D.C.

BAROnova

Series A in 2006
BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and based in Goleta, California. The company specializes in developing non-surgical and non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a simple endoscopic procedure. This device helps patients feel full more quickly, prolongs the sensation of fullness, and delays gastric emptying, thereby supporting weight loss efforts.

KFx Medical

Series A in 2005
KFx Medical specializes in the development and manufacturing of innovative soft tissue fixation implants aimed at orthopedic sports medicine. The company provides a system designed for tissue fixation, offering products that can be directly placed into bones, both with and without sutures. These implants are utilized in various orthopedic surgical procedures, allowing surgeons to effectively reattach tissue in areas such as the shoulder, knee, foot, and ankle. By collaborating with leading orthopedic surgeons, KFx Medical focuses on advancing technology and delivering reliable surgical implants, ultimately aiming to enhance surgical outcomes for patients.

HealthMedia

Venture Round in 2005
Founded in 1998, by Dr. Victor Strecher, HealthMedia® has developed a methodology and technology that effectively emulates a health coaching session, without the coach. Our one-of-a-kind programs possess the scalability of web content and deliver the efficacious outcomes a health coaching program receives.

Accuri Cytometers

Series A in 2005
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.

CardioMEMS

Series B in 2003
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Their technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Their miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.

Asterand

Series C in 2003
Asterand Bioscience is the leading global provider of high quality, well characterized human tissue and human tissue-based research solutions to drug discovery scientists. Our mission is to provide human-based solutions to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with an increased likelihood of clinical success. Asterand Bioscience has a well-established human tissue heritage, having been formed in 2006 through the merger of Asterand (founded 2000), a human tissue biorepository and Pharmagene (founded 1996) a human tissue-based drug discovery company. With this background and capability in human tissue procurement, characterization and research tools, Asterand Bioscience is uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical, biotechnology and diagnostic companies, as well as academia. From our offices in Detroit, MI and Royston, U.K., our employees focus on providing services and products to accelerate drug discovery research from target identification through compound evaluation and drug safety.

NeoGuide Systems

Series B in 2003
NeoGuide Systems Inc. develops robotic endoscopic technology for natural orifice transluminal endoscopic surgery. Its technology is used in colonoscopy application to provide access to abdominal and thoracic cavities. The company was founded in 2000 and is based in San Jose, California.